PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.

By Sarbari Acharya, S. Sahoo. Advanced Drug Delivery Reviews, 2011

1,049 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers (2012, neutral): “The enhanced permeability and retention effect is considered to be the “gold standard” for developing new anticancer agents.(56) Active targeting involves targeting ligands which are coupled at the surface of magnetic nanoparticles to interact with receptors that are overexpressed at their target si”
PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “The development of nanoparticles for the delivery of contrast agents has emerged in recent years since the possibility of the production of multifunctional nanoparticles able to specifically target the tumor [7].”
Cancer Nanomedicine: From Targeted Delivery to Combination Therapy (2015, background): “The enhanced permeability and retention (EPR) effect refers to the fact that tumors retain more polymeric NPs, proteins, liposomes, and micelles than other tissues [10,37,38].”
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance (2020, methodology): “…2006; Saad et al., 2008; Chen et al., 2009; Choi et al., 2019) NF-κB inhibitors (pyrrolidine dithiocarbamate/curcumin) (Fan et al., 2010; Misra and Sahoo, 2011; Zhao et al., 2019) Activate pro-apoptosis pathway Ceramide (Devalapally et al., 2007; van Vlerken et al., 2010) p53 gene therapy…”